<DOC>
	<DOCNO>NCT00005982</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Phase II trial study effectiveness 506U78 treat patient recurrent refractory cutaneous T-cell lymphoma</brief_summary>
	<brief_title>506U78 Treating Patients With Recurrent Refractory Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate , failure-free survival , progression-free survival patient recurrent refractory cutaneous T-cell lymphoma treat 506U78 . II . Determine toxicity drug patient . III . Study pharmacokinetics drug patient . OUTLINE : This multicenter study . Patients receive 506U78 IV 2 hour day 1 , 3 , 5 . Treatment continue every 28 day 6 course absence disease progression unacceptable toxicity . Patients follow every 6 month . PROJECTED ACCRUAL : A total 12-35 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Histologically confirm relapsed refractory cutaneous Tcell lymphoma Large cell transformation cutaneous Tcell lymphoma allow No active CNS disease Performance status Zubrod 02 Absolute neutrophil count least 1,000/mm^3* Platelet count least 100,000/mm^3* Bilirubin great 1.5 time upper limit normal ( ULN ) SGPT great 2.5 time ULN Creatinine clearance great 50 mL/min No history symptomatic cardiac dysfunction No history pericardial effusion HIV negative No grade 2 great sensory motor neuropathy No history seizures No malignancy within past 5 year except curatively treat basal cell carcinoma skin carcinoma situ cervix No medical , psychiatric , social condition would preclude study No concurrent serious illness active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior stem cell bone marrow transplantation ( BMT ) No 1 prior immunotherapy regimen No 3 prior systemic regimen denileukin diftitox At least 3 week since prior biologic therapy No concurrent BMT No prior 506U78 No 3 prior systemic chemotherapy regimens comprise follow : Oral methotrexate Topical mechlorethamine At least 3 week since prior chemotherapy No concurrent chemotherapy At least 3 week since prior anticancer endocrine therapy No concurrent topical systemic steroid At least 3 week since prior radiotherapy No 3 prior systemic regimen comprise follow : Total skin electron beam therapy Spot radiotherapy No 3 prior systemic regimen comprise follow : Oral retinoids Ultraviolet therapy ( PUVA ) At least 3 week since prior anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>